Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
Microbot Medical reported greater than 100% sequential revenue and customer growth in the second quarter of 2026, driven by the Full Market Release of the LIBERTY Endovascular Robotic System. Adoption expanded into health systems across Massachusetts, North Carolina, Michigan, and Pennsylvania, while procedure volumes increased at existing sites following the April launch. The company secured a government channel partnership with Lovell Government Services to target federal healthcare systems and received Israeli regulatory clearance, adding to plans to expand U.S.
Key figures
- Fmr date
- April 13, 2026
- Qoq revenue growth
- >100%
- Qoq customer growth
- >100%
- Current sales territories
- 8
- Planned sales territories
- 12
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.